三阴乳腺癌的临床研究新进展(1)
【中图分类号】R737.98 【文献标识码】A 【文章编号】1672-3783(2012)01-0230-01【摘要】 三阴乳腺癌( Triple negative breast cancer, TNBC)是指ER、PR、Her-2三者均为阴性表达的乳腺癌。TNBC组织学分级较高、内脏转移率高，缺乏有效治疗手段，内分泌治疗与针对Her-2的分子靶向治疗均不理想，因而预后较差。相关研究表明，TNBC对化疗较为敏感，尤以紫杉类、蒽环类、铂类为代表。针对EGFR等靶点的靶向治疗正在研究中，可能会发挥较好的治疗效果。而传统的中医药治疗也可以改善TNBC的预后。本文就TNBC的临床研究新进展做一综述。
【关键词】 三阴乳腺癌 综述 病理 治疗
New clinical research progress in triple negative breast cancer
【Abstract】 Triple negative breast cancer refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2 (Her-2). Triple negative patients usually have a high incidence of visceral metastases, high histologic grade and poor prognosis. Lacking of incretion treatment and the target spot of targeted therapy to aim at Her-2, the select of the treatment is limited. Now some research have shown that TNBC may be sensitive to neoadjuvant chemotherapy, especially for the taxlo、anthracylines and platinum drugs. The research of the targeted therapy, which aimed at targets such as EGFR, is under research and this therapy may have a relative positive effect on the treatment.This article is to sum up the clinical research progress in triple negative breast cancer ......
您现在查看是摘要页，全文长 4449 字符。